Proton Pump Inhibitors Prescribing Behaviors and Rationalization Strategies Among Healthcare Providers in Southeast Asia
Authors:
- Duc Trong QuachDQDuc Trong Quach
- Tien Manh HuynhTHTien Manh Huynh
- Augusto Jose G. GalangAGAugusto Jose G. Galang
- Hang Viet DaoHDHang Viet Dao
- Sakkarin ChirapongsathornSCSakkarin Chirapongsathorn
- Phuripong KijdamrongthumPKPhuripong Kijdamrongthum
- Rahela Ambaras KhanRKRahela Ambaras Khan
- Andrew Ming‐Liang OngAOAndrew Ming‐Liang Ong
- Wee Kooi CheahWCWee Kooi Cheah
- Kalwinder Singh KhairaKKKalwinder Singh Khaira
- So Fie TanSTSo Fie Tan
- Jose SollanoJSJose Sollano
Open Access
- 2 June 2026
- journal article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (3) , e70274
Abstract
Despite widespread use, real‐world evidence regarding proton pump inhibitor (PPI) prescribing and rationalization practices in Southeast Asia (SEA) remains limited; therefore, we aimed to characterize current prescribing behaviors and rationalization strategies among healthcare professionals in the region. The SEA PPI Rationalisation Working Group developed and disseminated an online questionnaire via professional networks across SEA to collect data on respondent demographics, PPI prescribing practices, and rationalization approaches; instrument reliability testing produced a Cronbach's α of 0.799 and content validity was confirmed by a panel of 10 gastroenterology experts with complete agreement on relevance and clarity (I‐CVI, kappa, SCVI/Ave = 1.0). K‐mode clustering was applied to delineate prescribing patterns. Of 869 responses received, 763 valid entries were analyzed (response rate 87.8%), 49% of whom were gastroenterologists. PPIs were most frequently prescribed for gastroesophageal reflux disease (67.8%) and peptic ulcer disease (43.8%); 48.9% of respondents reported long‐term PPI use, while 59.2% reported reassessment of indications at every follow‐up visit. Common rationalization strategies comprised dose tapering (46.8%), on‐demand administration (45.9%), and step‐down to antacids or alginates (44.8%). Cluster analysis identified two distinct prescriber profiles: proactive prescribers ( n = 326, 42.7%), who adhered to clinical guidelines, implemented individualized dosing, and routinely reassessed therapy; and conservative prescribers ( n = 437, 57.3%), who employed PPIs more restrictively and engaged less frequently in rationalization. The considerable variability in PPI prescribing and rationalization practices across SEA underscores the need for a regional consensus to promote evidence‐based practice.Keywords
This publication has 28 references indexed in Scilit:
- AGA Clinical Practice Guideline on Surveillance of Barrett’s EsophagusGastroenterology, 2025
- Good clinical practice recommendations for proton pump inhibitor prescription and deprescription. A review by experts from the AMGRevista de Gastroenterología de México (English Edition), 2025
- Factors influencing healthcare providers’ behaviours in deprescribing: a cross-sectional studyJournal of Pharmaceutical Policy and Practice, 2024
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert ReviewGastroenterology, 2022
- Consensus statements and recommendations on the management of mild‐to‐moderate gastroesophageal reflux disease in the Southeast Asian regionJGH Open, 2021
- Proton pump inhibitor use among patients at risk of peptic ulcer bleeding: a nationwide register-based studyScandinavian Journal of Gastroenterology, 2021
- The Use and Misuse of Proton Pump Inhibitors: An Opportunity for DeprescribingJournal of the American Medical Directors Association, 2021
- The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological AssociationGastroenterology, 2017
- Guidelines for Prevention of NSAID-Related Ulcer ComplicationsAmerican Journal of Gastroenterology, 2009
- Is the CVI an acceptable indicator of content validity? Appraisal and recommendationsResearch in Nursing & Health, 2007